Upregulation of Mitochondrial Uncoupling Protein-2 by the AMP-Activated Protein Kinase in Endothelial Cells Attenuates Oxidative Stress in Diabetes by Xie, Zhonglin et al.
Upregulation of Mitochondrial Uncoupling Protein-2 by
the AMP-Activated Protein Kinase in Endothelial Cells
Attenuates Oxidative Stress in Diabetes
Zhonglin Xie,
1 Junhua Zhang,
1 Jiliang Wu,
2 Benoit Viollet,
3 and Ming-Hui Zou
1
OBJECTIVE—Recent evidence suggests that the AMP-activated
protein kinase (AMPK) is an important therapeutic target for
diabetes. The present study was conducted to determine how
AMPK activation suppressed tyrosine nitration of prostacyclin
synthase in diabetes.
RESEARCH DESIGN AND METHODS—Conﬂuent human
umbilical vein endothelial cells (HUVECs) or mice were treated
with 5-amino-4-imidazole carboxamide riboside (AICAR) for the
detection of AMPK phosphorylation and the expression of mito-
chondrial uncoupling protein (UCP)-2.
RESULTS—Exposure of HUVECs to high glucose (30 mmol/l)
increased superoxide anions (O2
) and prostacyclin synthase
nitration. In addition, overexpression of constitutively active
AMPK (Ad-CA-AMPK) or the addition of AICAR reduced both
O2
 and prostacyclin synthase nitration caused by high glucose,
whereas adenoviral overexpression of dominant-negative AMPK
mutants (Ad-DN-AMPK) enhanced the latter effects of high
glucose. Exposure of HUVECs to either AICAR or metformin
caused AMPK-dependent upregulation of both UCP-2 mRNA and
UCP-2 protein. Furthermore, overexpression of UCP-2 signiﬁ-
cantly ablated both O2
 and prostacyclin synthase nitration
triggered by high glucose. Furthermore, overexpression of Ad-
CA-AMPK increased, whereas overexpression of Ad-DN-AMPK
inhibited AICAR-induced phosphorylation of p38 kinase at
Thr180/Tyr182. Inhibition of p38 kinase with SB239063, which
had no effect on AICAR-induced AMPK-Thr172 phosphorylation,
dose dependently suppressed AICAR-induced upregulation of
UCP-2, suggesting that AMPK lies upstream of p38 kinase.
Finally, AICAR markedly increased UCP-2 expression and re-
duced both O2
 and prostacyclin synthase nitration in diabetic
wild-type mice but not in their AMPK2-deﬁcient counterparts in
vivo.
CONCLUSIONS—We conclude that AMPK activation increases
UCP-2, resulting in the inhibition of both O2
 and prostacyclin
synthase nitration in diabetes. Diabetes 57:3222–3230, 2008
A
MP-activated protein kinase (AMPK) is a het-
erotrimer made up of -, -, and -subunits,
each of which has at least two isoforms (1–3).
Increases in the AMP-to-ATP ratio activate
AMPK by a number of mechanisms, including direct
allosteric activation and -subunit phosphorylation (at
Thr172) by at least two AMPK kinases (i.e., LKB1 and
calcium calmodulin–dependent kinase kinase [caMKK])
(4). AMPK is ubiquitous and is activated in a variety of cell
types by inhibition of ATP production (i.e., anoxia and
ischemia) or acceleration of ATP consumption (i.e., mus-
cle contraction and fasting). As ﬁrst noted by Hardie and
Carling (1), AMPK activation appears to be a fundamental
component of cellular responses to stresses that threaten
cell viability. AMPK is phosphorylated and activated in
various tissues by hormones acting through Gq receptors
(5), adiponectin (6,7), leptin (8,9), - and -adrenoreceptor
agonists (10), metformin (11), thiazolidinediones (12), and
oxidants, such as peroxynitrite (ONOO
) (13,14) and H2O2
(15). Activation of AMPK leads to the phosphorylation of a
number of target molecules, resulting in, among other
things, increased fatty acid oxidation and muscle glucose
transport (to generate more ATP) and inhibition of various
biosynthetic processes (to conserve ATP) (16). Increasing
evidence suggests that the functions of AMPK are beyond
energy metabolism. For example, both endothelial nitric
oxide (NO) synthase (eNOS) and neuronal NO synthase
(nNOS) are targets of AMPK in the endothelium and
muscle (17,18). Winder and colleagues (19,20) have shown
that treatment of rats with 5-amino-4-imidazole carbox-
amide riboside (AICAR) increases the expression of a
wide variety of proteins in muscle, including the GLUT-4
glucose transporter and several mitochondrial oxidative
enzymes. AMPK activation has also been shown to in-
crease the expression of mitochondrial uncoupling protein
(UCP)-2 in liver after infection with constitutively active
AMPK (Ad-CA-AMPK) (21). Similar effects of AMPK on
UCP2 and UCP3 have been reported in skeletal muscle
(22).
Strong accumulating evidence suggests that oxidative
stress, deﬁned as increased formation of reactive oxygen
species (ROS) and reactive nitrogen species (RNS) and/or
decreased antioxidant potentials, plays an important role
in the development of diabetic complications (23–27). This
hypothesis is supported by the ﬁnding that many biochem-
ical pathways strictly associated with hyperglycemia (glu-
cose auto-oxidation, polyol pathway, prostanoid synthesis,
and protein glycation) increase the production of free
radicals and oxidants (27). The functions of many proteins
are likely affected by increased oxidant levels. We have
found (24–26) that prostacyclin synthase, an enzyme re-
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3222 DIABETES, VOL. 57, DECEMBER 2008leasing vasoprotective prostacyclin, is particularly suscep-
tible to tyrosine nitration by RNS, including ONOO
.I n
cultured endothelial cells, hyperglycemic medium in-
creases the levels of nitrated prostacyclin synthase and
decreases prostacyclin synthase activity (20,23). Tyrosine
nitration of prostacyclin synthase and consequent throm-
boxane receptor activation are thought to be important
mechanisms contributing to the initiation and progression
of vascular complications in diabetes (rev. in 23). This is
because of the downregulation of the protective actions of
NO and prostacyclin and accumulation of nonmetabolized
prostaglandin H2, which promotes platelet aggregation,
atheroma accumulation, and thrombus formation (23).
Emerging data support a role for ROS and RNS in cell
signaling. Lee and Griendling (28) found that angiotensin II
augments O2
 production in smooth muscle cells via
NADH/NADPH oxidase-like enzymatic activity. This enzy-
matic system now appears to be involved in a number of
“maladaptive” characteristics of atherosclerosis, such as
PDGF-induced cell proliferation (29), smooth muscle cell
hypertrophy (30), diabetic retinopathy (31), and impaired
NO bioactivity (32). Our earlier results had also demon-
strated that pathologically relevant concentrations of
ONOO
 are capable of activating AMPK independently of
changes in AMP/ATP and that ONOO
-dependent AMPK
activation occurs during hypoxia reoxygenation (13) and
in metformin-treated endothelial cells (33). However, the
consequences of AMPK activation on cellular oxidative
stress remain to be determined. In the present study, we
provide evidence that AMPK prevents oxidative stress
associated with diabetes, in part, by upregulating mito-
chondrial UCP-2.
RESEARCH DESIGN AND METHODS
A full description of the research design and methods, including adenoviral
infection, RT-PCR of UCP-2 mRNA, prostacyclin synthase activity assays, NO
bioactivity, immunocytochemistry, and high-performance liquid chromatogra-
phy (HPLC) detection of 3-nitrotyrosine can be found in an online appendix
available at http://dx.doi.org/10.2337/db08-0610.
The animal protocol was reviewed and approved by the institutional animal
care and use committee. Male AMPK2 knockout (KO) (AMPK
/) mice,
which had been cross-bred with C57BL6 mice, were bred at the animal house
of the University of Oklahoma Health Sciences Center. Their littermates,
C57BL6 mice, were obtained from The Jackson Laboratories (Bar Harbor,
ME). Mice were housed in temperature-controlled cages with a 12-h light/dark
cycle and given free access to water and normal chow. Mice aged 10 weeks
were randomly divided into control and treated groups.
AMPK2 KO mice and age-matched C57BL/6 mice were used to study
whether AICAR attenuates diabetes-enhanced UCP-2 expression and prosta-
cyclin synthase nitration. The mice were made diabetic after ﬁve consecutive
injections of 50 mg/kg streptozotocin (STZ) in citrate buffer, pH 4.5. Nondia-
betic mice were injected with a comparable volume of citrate buffer. Glucose
levels were measured in tail blood by a Free Style blood glucose monitoring
system (TheraSense, Alameda, CA). Hyperglycemia was conﬁrmed by non-
fasting blood glucose 200 mg/dl (11 mmol/l) 1 week after the initial STZ
injection. The nondiabetic and diabetic mice were randomly divided into three
groups: control, STZ/untreated, and STZ but treated with AICAR (250 mg 
kg
1  day
1 s.c.). Six weeks later, the animals were killed, and the aorta was
collected for analysis.
Cell culture. Human umbilical vein endothelial cells (HUVECs) (American
Type Culture Collection, Rockville, MD) were cultured in endothelial basal
media (EBM). When they reached conﬂuence, the cells were maintained in 1%
fetal calf serum and exposed to normal glucose (5.5 mmol/l) or high glucose
(30 mmol/l) for 3–7 days, during which the medium was changed every 2 days.
Control groups (to account for media hyperosmolarity) were exposed to
mannitol (24.5 mmol/l) in normal medium containing glucose (5.5 mmol/l).
After incubation, the media were collected, and assays were conducted as
described below. For measurements of O2
 and cyclic GMP, the growth
medium was replaced by PBS containing no glucose. Unless otherwise noted,
AB
C D
S
u
p
e
r
o
x
i
d
e
 
a
n
i
o
n
s
(
1
0
-
1
0
 
m
o
l
/
m
g
 
p
r
o
t
e
i
n
/
m
i
n
)
0
5
10
15 #
♣
0
5
10
15
20
C
y
c
l
i
c
 
G
M
P
(
p
m
o
l
/
m
g
 
p
r
o
t
e
i
n
)
#
♣
6
-
k
e
t
o
-
P
G
F
1
α
0
100
200
300
400
#
♣
8
-
i
s
o
p
r
o
s
t
a
n
e
 
(
p
g
/
m
g
 
p
r
o
t
e
i
n
)
0
400
800
1200
# # #
1600
♣
FIG. 1. AMPK activation with 0.5 mmol/l AICAR reduces high glucose–induced oxidative stress and prostacyclin synthase nitration in HUVECs.
Conﬂuent HUVECs were exposed to 5 mmol/l D-glucose (NG), 30 mmol/l D-glucose (HG), or 5 mmol/l D-glucose plus 25 mmol/l mannitol (OG) for
72 h with or without 0.5 mmol/l AICAR. After the incubation, O2
 (A), cyclic GMP (NO bioactivity) (B), 8-iso-PGF2 (f, AICAR; , AICAR)
(C), and prostacyclin synthase activity (as reﬂected by the conversion of PGH2 to 6-keto-PGF1)( D) were assayed (n  12, #P < 0.01 high glucose
vs. normal glucose, P < 0.01 high glucose vs. high glucose plus AICAR. IP, immunoprecipitation; PGIS, prostacyclin synthase; WB, Western blot).
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DIABETES, VOL. 57, DECEMBER 2008 3223these measurements were performed on cells or the PBS bathing cells, which
were stimulated by the calcium ionophore A23187 (10
5 mol/l, 2 h).
Adenovirus infection. HUVECs were infected with adenovirus encoding
either Ad-DN-AMPK or Ad-UCP-2, as described previously (13,14,33). Adeno-
viruses encoding green ﬂuorescent protein (GFP) served as a control.
Measurement of intracellular ROS. Intracellular O2
 was measured using
the dihydroethidium (DHE) ﬂuorescence/HPLC assay (34) with minor modi-
ﬁcation. Brieﬂy, HUVECs were incubated with 0.5 mol/l DHE for 30 min,
harvested, and then methanol extracted. Oxyethidium (a product of DHE and
O2
) and ethidium (a product of DHE auto-oxidation) were separated and
quantiﬁed using a C-18 HPLC column (mobile phase: gradient of acetonitrile
and 0.1% triﬂuoroacetic acid). O2
 production was determined by the
conversion of DHE into oxyethidium. ROS production in aorta was assayed
using 5 mol/l lucigenin chemiluminescence as described previously (24–26).
Statistical analysis. Statistical comparison was performed using a one- or
two-way ANOVA, and intergroup differences were determined using the
Bonferroni inequality. Values are expressed as means  SE. P  0.05 was
considered signiﬁcant.
RESULTS
AICAR reduces high glucose–induced oxidative stress in
HUVECs. Our earlier studies (24,25) demonstrated that
hyperglycemia not only increases O2
 production and
tyrosine nitration of prostacyclin synthase but also re-
duces NO bioactivity, as determined by cyclic GMP levels.
A subsequent study (32) revealed that the AMPK activator,
metformin, dramatically attenuates the latter effect. To
understand whether the beneﬁcial effects of AMPK activa-
tion may be attributable to its ability to reduce oxidative
stress, we tested the effect of AICAR on markers of
oxidative stress in HUVECs. Conﬂuent HUVECs were
exposed to 5 mmol/l D-glucose (normal glucose), 30
mmol/l D-glucose (high glucose), or 5 mmol/l D-glucose
plus 25 mmol/l mannitol (OG) for 72 h with or without 0.5
mmol/l AICAR. High glucose but not the osmotic control
(i.e., 5 mmol/l D-glucose plus 25 mmol/l mannitol) caused a
threefold increase of O2
 in HUVECs (Fig. 1A). Adminis-
tration of 0.5 mmol/l AICAR had no effect on basal O2

production but attenuated high glucose–enhanced O2

release. We also examined the effect of AICAR on NO
bioactivity, which depends on the overall production
and/or depletion of NO by O2
. In line with elevated O2

release, high glucose signiﬁcantly reduced the levels of
cyclic GMP, and AICAR prevented this effect (Fig. 1B).
Furthermore, AICAR increased the phosphorylation of
eNOS-Ser1177, whereas it had no effects on the total
amount of eNOS protein in high glucose–exposed
HUVECs (data not shown). These results suggest that
AICAR might maintain NO bioactivity under high glucose
conditions by increasing NO release and/or counteracting
oxidative stress.
Further analysis of the antioxidant effects of AICAR was
performed by measuring 8-iso-prostaglandin F2,a
marker of lipid peroxidation. As shown in Fig. 1C, high
glucose markedly increased 8-iso-prostaglandin F2 lev-
els. Although AICAR had no effect on basal levels of
8-iso-prostaglandin F2, it partially but signiﬁcantly re-
duced high glucose–induced increases in 8-iso-prostaglan-
din F2. AICAR did not completely abolish high glucose–
enhanced 8-iso-prostaglandin F2 in HUVECs (P  0.05,
normal glucose vs. high glucose plus AICAR). To under-
stand whether AICAR acts as an oxidant scavenger, we
exposed HUVECs to chemically synthesized ONOO
.
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FIG. 2. Chronic administration of AICAR attenuates high glucose–enhanced prostacyclin synthase nitration in HUVECs. Conﬂuent HUVECs were
exposed to 0.5 mmol/l AICAR for the indicated time. Prostacyclin synthase, nitrated prostacyclin synthase, and prostacyclin synthase activity
were assayed as described in RESEARCH DESIGN AND METHODS. A: Effect of AICAR on prostacyclin synthase protein expression in HUVECs; n  7. B:
Effect of 0.5 mmol/l AICAR on prostacyclin synthase activity in HUVECs; n  7. , Control; f, AICAR. C and D: AICAR administration attenuates
high glucose–enhanced prostacyclin synthase nitration in HUVECs; n  5, #P < 0.01 high glucose vs. normal glucose, P < 0.01 high glucose vs.
high glucose plus AICAR. IP, immunoprecipitation; PGIS, prostacyclin synthase; WB, Western blot.
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 signiﬁcantly increased 8-iso-prostaglandin F2
levels; however, cotreatment with AICAR did not alter this
effect (Fig. 1C). Additional experiments revealed that
AICAR had no effect on the reduction of cytochrome C
caused by xanthine/xanthine oxidase (data not shown).
Thus, the reduction of oxidative stress by AICAR cannot
be attributed to its ability to directly scavenge O2
 or
ONOO
.
AICAR inhibits high glucose–induced nitration and
inactivation of prostacyclin synthase. Our earlier stud-
ies (24,25) had demonstrated that high glucose increases
tyrosine nitration of prostacyclin synthase, which inhibits
prostacyclin synthase activity. Analysis of 6-keto-PGF1
concentrations revealed that high glucose, but not manni-
tol, signiﬁcantly suppressed prostacyclin synthase activity
in HUVECs (Fig. 1D). Interestingly, 1 mmol/l AICAR sig-
niﬁcantly attenuated high glucose–induced reduction of
6-keto-PGF1 but had no effect on the levels of 6-keto-
PGF1 in cells exposed to mannitol (Fig. 1D).
We next determined whether increased prostacyclin
synthase activity was due to increased prostacyclin syn-
thase expression. Under normal glucose conditions, 1
mmol/l AICAR (1- to 72-h exposure) altered neither pros-
tacyclin synthase protein levels (Fig. 2A) nor prostacyclin
synthase activity (Fig. 2B). These results suggest AICAR
had no effect on prostacyclin synthase activity or prosta-
cyclin synthase expression in HUVECs.
Because high glucose exposure increased prostacyclin
synthase nitration and inactivation, we next determined
whether the protective effects of AICAR on prostacyclin
synthase activity were due to the reduction of prostacyclin
synthase nitration caused by high glucose. Consistent with
the idea that AMPK reduces oxidative stress, 0.5 mmol/l
AICAR prevented prostacyclin synthase nitration in
HUVECs exposed to high glucose (Fig. 2C and D).
AMPK activation is required for AICAR-induced re-
duction of oxidative stress. Incubation of HUVECs with
AICAR resulted in time-dependent AMPK activation, as
determined by Thr172 phosphorylation of AMPK (Fig. 3A).
Similarly, a 24-h incubation with 1 mmol/l metformin
markedly increased Thr172-AMPK phosphorylation (Fig.
3A). Because either AICAR (Fig. 1A) or metformin (data
not shown) signiﬁcantly reduced ROS production under
high glucose conditions, we tested whether AMPK activa-
tion was required for this antioxidant effect. Under normal
glucose conditions, inhibition of AMPK by adenoviral
overexpression of dominant-negative AMPK (Ad-DN-
AMPK) signiﬁcantly increased ROS in HUVECs, whereas
GFP overexpression had no effect (Fig. 3B). Moreover,
Ad-DN-AMPK overexpression signiﬁcantly accentuated
high glucose–induced ROS production (Fig. 3B). These
results suggest that AMPK functions as an endogenous
protector against ROS in endothelial cells.
AMPK attenuates high glucose–induced oxidative
stress and prostacyclin synthase nitration through
upregulation of UCP-2. To further investigate the mech-
anism by which AMPK activation reduces oxidative stress,
we analyzed UCP-2 expression in HUVECs. Under normal
conditions, UCP-2 mRNA was abundant, but very low
levels of UCP-2 protein were detected (Fig. 3C). However,
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FIG. 3. AICAR-induced UCP-2 expression in HUVECS is AMPK dependent. A: AMPK activation by AICAR or metformin. The blot is a
representative blot of four blots from four individual experiments. B: Effect of Ad-DN-AMPK on O2
 production induced by high glucose (n  3,
#P < 0.05 normal glucose vs. high glucose or high glucose/Ad-GFP, P < 0.05 Ad-GFP/high glucose/AICAR vs. GFP/high glucose or high glucose,
‡P < 0.05 Ad-DN-AMPK vs. normal glucose, †P < 0.05 AD-DN-AMPK/AICAR/high glucose vs. Ad-GFP/high glucose/AICAR). C: Increase of UCP-2
mRNA by AICAR in HUVECs (n  3, P < 0.05 control vs. metformin or AICAR). D: AICAR-enhanced UCP-2 expression is AMPK dependent (n 
3, *P < 0.05 vs. GFP vs. GFP plus AICAR, †P < 0.05 AICAR plus GFP vs. AICAR plus AD-DN-AMPK).
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both UCP-2 mRNA (Fig. 3C) and UCP-2 protein expression
(Fig. 3D). Importantly, inhibition of AMPK with Ad-DN-
AMPK, but not control Ad-GFP, signiﬁcantly attenuated
AICAR-induced UCP-2 expression, implying that AMPK
upregulates UCP-2 expression in HUVECs (Fig. 3D).
Next, we tested whether adenoviral overexpression of
UCP-2 in HUVECs altered high glucose–induced ROS
production. Overexpression of Ad-UCP-2 markedly in-
creased UCP-2 protein in HUVECs (Fig. 4A). In addition,
adenoviral overexpression of UCP-2 signiﬁcantly reduced
high glucose–induced increases in ROS (Fig. 4B) and
3-nitrotyrosine (Fig. 4C), with GFP overexpression having
no effect on either parameter. Consistent with this result,
UCP-2 overexpression markedly inhibited high glucose–
induced prostacyclin synthase nitration (Fig. 4D) and
prostacyclin synthase inactivation (Fig. 4E).
Activation of p38 kinase is required for AMPK-
dependent UCP-2 expression. The fact that both AMPK
and p38 kinase are activated by extracellular stresses
(e.g., hypoxia/reoxygenation and osmotic stress) (34,35)
prompted us to investigate whether p38 kinase is required
for AMPK-dependent UCP-2 expression. As shown in Fig.
5A, the phosphorylation of p38 kinase at Thr180/Tyr182
was markedly increased for up to 4 h after AICAR treat-
ment. In parallel, AICAR increased the phosphorylation of
c-Jun, a downstream enzyme of p38 kinase. Adenoviral
overexpression of constitutively active AMPK for 24 h
before AICAR treatment (2 mmol/l for 2 h) resulted in an
increase in c-Jun and p38 kinase phosphorylation that was
even greater than that elicited by AICAR alone (Fig. 5B).
Conversely, overexpression of Ad-DN-AMPK inhibited
AICAR-induced phosphorylation of p38 kinase and c-Jun
(Fig. 5B).
To determine whether p38 kinase is required for AMPK-
dependent UCP-2 expression, we treated HUVECs with
SB239063, a potent p38 kinase inhibitor. Incubation of
HUVECs with SB239063 abolished AICAR-induced phos-
phorylation of both p38 kinase (Fig. 5C) and c-Jun (data
not shown). Importantly, SB239063 also suppressed
AICAR-induced upregulation of UCP-2 in a dose-depen-
dent manner (Fig. 5D). When used at concentrations up to
20 mol/l, SB239063 did not alter AICAR-induced AMPK-
Thr172 phosphorylation (Fig. 5E), suggesting that AMPK
lies upstream of p38 kinase.
Chronic stimulation of AMPK with AICAR attenuates
diabetes-induced oxidative stress and prostacyclin
synthase nitration. To extend our in vitro ﬁndings, we
investigated the effect of AICAR on prostacyclin synthase
nitration and UCP-2 expression associated with STZ-in-
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
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KO mice were subjected to ﬁve consecutive injections of
50 mg/kg STZ in citrate buffer, pH 4.5, or an equivalent
volume of citrate buffer. Two weeks after STZ injection,
animals received daily subcutaneous injections of 250
mg/kg AICAR (n 	 7) or a corresponding volume of 0.9%
NaCl for 6 weeks. One week after injection, mice admin-
istered STZ had signiﬁcantly higher serum glucose levels
than their control counterparts (wild type, 488  25 vs.
119  7 mg/dl, P  0.001, n 	 11; AMPK2 KO, 493  27
vs. 129  11 mg/dl, P  0.001, n 	 9). In addition, diabetic
animals had signiﬁcantly lower body weights (wild type,
16.0  0.8 vs. 18.8  1g ,14.9%, P  0.05, n 	 11;
AMPK2 KO, 15.8  0.9 vs. 17.9  0.7 g, P  0.05, n 	 10)
and plasma insulin concentrations (wild type, 0.3  0.1 vs.
1.2  0.2 ng/ml, P  0.01, n 	 11; AMPK2 KO, 0.4  0.2
vs. 1.0  0.2 ng/ml) than controls. Diabetic and nondia-
betic animals had a similar heart weight (wild type, 70 
3.5 vs. 75  2.6 mg). Comparison of AICAR and non-
AICAR–treated diabetic mice revealed that both groups
had similar blood glucose levels (wild type, 488  25 vs.
461  28 mg/dl; AMPK2 KO, 493  27 vs. 509  27 mg/dl,
P  0.001, n 	 9), water consumption (16.1  0.7 vs.
15.1  0.5 ml/day), and body weight (17.5  0.8 vs. 19.1 
0.1 g).
Next, isolated aortas were analyzed for O2
 levels,
prostacyclin synthase nitration, and UCP-2 expression. A
comparison of aortas from nondiabetic C57BL6 mice and
AMPK2 KO mice revealed that AMPK2 KO aortas ex-
hibited higher O2
 levels and prostacyclin synthase nitra-
tion but had lower levels of prostacyclin synthase activity
(Fig. 6A–C). Compared with aortas from nondiabetic mice,
those from diabetic mice had markedly increased O2

levels (Fig. 6A), increased prostacyclin synthase nitration
(Fig. 6C), and decreased prostacyclin synthase activity
(Fig. 6C)( P  0.01, n 	 7). STZ injection exacerbated
aortic O2
 levels and prostacyclin synthase nitration in
AMPK2 KO mice. Activation of AMPK with AICAR signif-
icantly inhibited O2
 release, prostacyclin synthase nitra-
tion, and prostacyclin synthase inactivation in diabetic
wild-type mice (P  0.01, n 	 7), but AICAR administra-
tion had no effect in AMPK2 KO mice. Taken together,
these results suggest that AMPK activation is required for
the suppression of aortic O2
 formation and prostacyclin
synthase nitration by AICAR in vivo.
Finally, to test whether UCP-2 participates in AMPK-
dependent reduction in oxidative stress associated with
diabetes, we performed immunohistochemical staining for
UCP-2 in aortas from wild-type and AMPK2 KO mice.
UCP-2 staining was very weak in aortic tissue from wild-
type mice, but was greatly increased by STZ injection,
suggesting that diabetes increases UCP-2 expression (Fig.
6D). Similar to the aortas from nondiabetic wild-type mice,
nondiabetic AMPK2 KO aortas had barely detectable
levels of UCP-2 (Fig. 6D). However, UCP-2 expression was
still barely detectable in AMPK2 KO mice with STZ-
induced diabetes (Fig. 6D). In accord with these results,
AICAR signiﬁcantly increased UCP-2 staining in both
nondiabetic and diabetic wild-type mice but had no effect
in AMPK2 KO mice, suggesting that AMPK is required for
UCP-2 expression in vivo.
Administration of catalase does not alter UCP-2 expres-
sion enhanced by high glucose. Because several cellular
types exhibited reduced AMPK activity in the presence of
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FIG. 5. p38 kinase is required for AMPK-dependent UCP-2 expression. A: Effects of AICAR on the phosphorylation of c-Jun and p38 kinase in
HUVECs. Conﬂuent HUVECs were treated with 0.5 mmol/l AICAR at times indicated. The blot is a representative of three blots from three
independent experiments. B: AICAR-increased phosphorylation of c-Jun and p38 is AMPK dependent. HUVECs were infected with either
Ad-AMPK-CA or AD-AMPK-DN. The blot is a representative of three blots from three independent experiments. C: Effects of SB239063 on
AICAR-enhanced phosphorylation of p38 in HUVECs. HUVECs were treated with 0.5 mmol/l AICAR in the presence or absence of different
concentrations of SB239063, a selective p38 inhibitor (n  4, #P < 0.05 AICAR vs. control, P < 0.05 AICAR vs. AICAR plus SB239063). D: Effects
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we next determined whether the addition of catalase
altered UCP-2 expression in HUVECs. As shown in Fig. 7,
short exposure (2 h) of HUVECs to high glucose signiﬁ-
cantly increased the phosphorylation of AMPK Thr172
along with increased detection of UCP-2 in HUVECs.
Administration of catalase altered neither AMPK phos-
phorylation nor UCP-2 expression in HUVECs exposed to
high glucose.
DISCUSSION
In the present study, we have found that AICAR, an
activator of AMPK, reduces oxidative stress (O2
 and
3-nitrotyrosine) and increases UCP-2 expression in cul-
tured endothelial cells and in aorta from diabetic mice. In
high glucose–exposed HUVECs, AMPK inhibition of O2

formation and prostacyclin synthase nitration was accom-
panied by increased NO bioactivity. These protective
effects of AMPK were conﬁrmed by the ﬁnding that AMPK
gene deletion not only exacerbated STZ-induced O2

production and prostacyclin synthase nitration but also
rendered AICAR incapable of protecting against increased
O2
 and prostacyclin synthase nitration. The ability of
AICAR to upregulate UCP-2 expression in diabetic C57BL6
mice but not in AMPK2 KO mice suggests that AMPK-
dependent UCP-2 expression is essential for reduction of
oxidative stress by AMPK.
UCPs are mitochondrial transporters that are present in
the inner mitochondrial membrane and belong to a family
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FIG. 7. Effects of catalase on high glucose–enhanced expression of
UCP-2 in HUVECs. Conﬂuent HUVECs were exposed to high glucose or
normal glucose in the presence or absence of 500 units/ml catalase for
2 h. The levels of AMPK-Thr172 and UCP-2 were examined in Western
blots by using the speciﬁc antibody (n  3–5, P < 0.05 normal glucose
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nucleotide transporters (36,37). Mild uncoupling of respi-
ration is known to diminish mitochondrial ROS formation
by complex I and II (37). Recent evidence implies that the
basic role of all UCPs is to prevent oxidative tissue injury
by reducing oxidative stress (37). A role for UCP-2 in the
downregulation of mitochondrial ROS production is plau-
sible, because available evidence suggests that this protein
is expressed in numerous mammalian tissues (37). Macro-
phages of leptin-deﬁcient ob/ob mice have low UCP-2
levels compared with those of normal mice, and these low
UCP-2 levels are associated with increased mitochondrial
ROS production (38). In addition, ROS levels in macro-
phages of UCP-2
/ mice (39) and muscle tissue of
UCP-3
/ mice (40,41) exceed wild-type levels. UCP-2 has
the ability to reduce ROS not only in mitochondria, but
also within the remainder of the cell and even in the
extracellular space (36,41,42). Duval et al. (44) have re-
cently shown that UCP-2–mediated uncoupling in endothe-
lial cells decreases extracellular ROS. Lee et al. (45) have
demonstrated that adenoviral transfer of the UCP-2 gene
into human airway epithelial cells profoundly suppresses
ROS generation, decreases NF-
B activity, enhances eNOS
transcription, and improves endothelium-dependent vas-
cular relaxation. Nevertheless, the molecular mechanisms
underlying UCP-2 expression remain poorly deﬁned. We
have provided the ﬁrst evidence that AMPK is essential for
UCP-2 expression in endothelial cells in vivo. In line with
this hypothesis, we have found that activation of AMPK
with AICAR prevents O2
 formation, NO inactivation, and
prostacyclin synthase nitration that accompanies pro-
longed exposure of HUVECs to high glucose. Also in line
with this hypothesis, pharmacological or genetic inhibition
of AMPK abolished the ability of AICAR to not only reduce
oxidative stress but also to upregulate UCP-2 expression.
The ﬁnding that STZ ampliﬁed O2
 production and pros-
tacyclin synthase nitration in AMPK2 KO mice strongly
suggests that AMPK suppresses oxidative stress. However,
the most conclusive evidence for this idea is provided by
the ﬁnding that AICAR failed to alter markers of oxidative
stress or UCP-2 expression in the AMPK- 2 KO mice.
Consistent with our results, AMPK activation has also
been shown to increase the expression of UCP-2 in liver
and in skeletal muscle (21,22). In pre-diabetic (impaired
glucose tolerance) subjects, a 1-year lifestyle diabetes
prevention program involving increased physiological ex-
ercise improves metabolic control and increases UCP-3
levels by twofold (45,46). Physiological exercise is known
to lead to AMPK activation (47,48). Activation of AMPK
leads to a reduction of oxidative stress and vascular
function.
AMPK is activated by multiple stimuli, including oxi-
dants such as ONOO
 and H2O2. Thus, the production of
oxidants might be required for AMPK-dependent UCP-2
expression. This idea is supported by the fact that UCP-2
was weakly expressed in endothelial cells from both
wild-type and AMPK2 KO mice (Fig. 6D). The ability of
STZ to induce aortic O2
 formation, prostacyclin synthase
nitration, and UCP-2 expression in wild-type mice, taken
with its inability to induce UCP-2 expression in AMPK2
KO mice (Fig. 6D), strongly suggests that intracellular ROS
activates AMPK, which then stimulates transcription of
the UCP-2 gene. Consistent with this hypothesis, recent
studies (49,50) suggested that O2
 itself activates UCP-2
within the matrix by an unspeciﬁed mechanism. We pro-
pose that ROS-activated AMPK, in return, limits ROS
production by increasing mitochondrial UCP-2 expression.
That is, AMPK-dependent UCP-2 upregulation is a com-
pensatory mechanism aimed at counteracting intracellular
oxidative stress. Collectively, our ﬁndings suggest that
AMPK is a physiological regulator of ROS that protects
endothelial cells against the adverse effects of hyperglyce-
mia by inhibiting the processes that generate oxidants.
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